Abstract:Invasive fungal diseases are a leading cause of mortality among immunocompromised populations. Treatment is notoriously difficult due to the limited number of antifungal drugs as well as the emergence of drug resistance. Tamoxifen (TAM), a selective estrogen receptor modulator frequently used for the treatment of breast cancer, has been found to have antifungal activities and may be a useful addition to the agents used to treat fungal infectious diseases. However, the molecular mechanisms underlying its antifungal actions remain obscure. Here, we screened for mutations that confer sensitivity to azole antifungal drugs by using the fission yeast Schizosaccharomyces pombe as a model and isolated a mutant with a mutation in cls1 ( ccr1 ), an allele of the gene encoding the NADPH-cytochrome P450 reductase Ccr1. We found that strains with a deletion of the ccr1 + gene exhibited hypersensitivities to various drugs, including antifungal drugs (azoles, terbinafine, micafungin), the immunosuppressor FK506, and the anticancer drugs TAM and 5-fluorouracil (5-FU). Unexpectedly, the overexpression of Ccr1 caused yeast cell resistance to TAM but not the other drugs tested here. Additionally, strains with a deletion of Ccr1 displayed pleiotropic phenotypes, including defects in cell wall integrity and vacuole fusion, enhanced calcineurin activity, as well as increased intracellular Ca 2+ levels. Overexpression of the constitutively active calcineurin suppressed the drug-sensitive phenotypes of the Δ ccr1 cells. Notably, TAM treatment of wild-type cells resulted in pleiotropic phenotypes, similar to those of cells lacking Ccr1. Furthermore, TAM inhibited Ccr1 NADPH-cytochrome P450 reductase activities in a dose-dependent manner. Moreover, TAM treatment also inhibited the NADPH-cytochrome P450 reductase activities of Candida albicans and resulted in defective cell wall integrity. Collectively, our findings suggest that Ccr1 is a novel target of TAM and is involved in the antifungal activity of TAM by regulating cell wall integrity in fission yeast.

Inhibition of MFN1 restores tamoxifen-induced apoptosis in resistant cells by disrupting aberrant mitochondrial fusion dynamics

Advances in mechanism of tamoxifen resistance in estrogen receptor-positive breast cancer

Mitogen-Activated Protein Kinase Phosphatase 1 Is Involved In Tamoxifen Resistance In Mcf7 Cells

Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells

Matrix Metalloproteinase-1 (MMP1) Upregulation through Promoter Hypomethylation Enhances Tamoxifen Resistance in Breast Cancer

Reversal of endocrine resistance via N6AMT1-NEDD4L pathway-mediated p110α degradation

TFAM Depletion Overcomes Hepatocellular Carcinoma Resistance to Doxorubicin and Sorafenib Through AMPK Activation and Mitochondrial Dysfunction.

MiR-592 Attenuates Tamoxifen Resistance in Breast Cancer Through PIK3CA-Mediated PI3K/AKT/mTOR Signaling Pathway

Sensitization To Tamoxifen By Tanshinone Iia In Tamoxifen-Resistant Breast Cancer Cells In Vitro

Tamoxifen promotes apoptosis and inhibits invasion in estrogen‑positive breast cancer MCF‑7 cells.

Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways.

MCAM/CD146 Promotes Tamoxifen Resistance in Breast Cancer Cells Through Induction of Epithelial–mesenchymal Transition, Decreased ERα Expression and AKT Activation

Role of monocarboxylate transporter I/lactate dehydrogenase B-mediated lactate recycling in tamoxifen-resistant breast cancer cells

N6-methyladenosine Modification of DYNLT1 Facilitates Tamoxifen Resistance in Luminal B Breast Cancer

Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features.

MitoTam induces ferroptosis and increases radiosensitivity in head and neck cancer cells

MFN1-dependent Alteration of Mitochondrial Dynamics Drives Hepatocellular Carcinoma Metastasis by Glucose Metabolic Reprogramming

Exosomes from tamoxifen-resistant breast cancer cells transmit drug resistance partly by delivering miR-9-5p

MFN2 Suppresses Cancer Progression Through Inhibition of Mtorc2/akt Signaling.

Monopolar Spindle 1 Contributes to Tamoxifen Resistance in Breast Cancer Through Phosphorylation of Estrogen Receptor Α.

NADPH-Cytochrome P450 Reductase Ccr1 Is a Target of Tamoxifen and Participates in Its Antifungal Activity via Regulating Cell Wall Integrity in Fission Yeast